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The ID protein, an inhibitor of basic helix-loop-helix (HLH) transcription factors, has been involved in multiple cellular processes.
To investigate the association between tumour advancement and ID expressions of uterine cervical cancers, the levels of ID-1, ID-2
and ID-3 mRNAs were determined by real-time reverse transcription-polymerase chain reaction and the histoscore with the
localisation of ID-1 was determined by immunohistochemistry and patient survival in 60 patients. ID-1 histoscores and mRNA levels
both significantly (Po0.05) increased in uterine cervical cancers according to clinical stage regardless of histopathological type or
lymph node metastasis. Furthermore, the 36-month survival rate of the 30 patients with high ID-1 was poor (60%), whereas that of
the other 30 patients with low ID-1 was significantly higher (83%). ID-1 histoscores and mRNA levels significantly (Po0.0001)
correlated with microvessel counts in uterine cervical cancers. Tumour cells show mostly diffuse to strong cytoplasmic expression of
ID-1 and also very faint expression in endothelial cells. Moreover, ID-1 expression not only correlated with microvessel counts but
also correlated significantly with histoscore. Therefore, ID-1 might work on tumour advancement through angiogenic activity and is
considered to be a candidate for a prognostic indicator in uterine cervical cancers.
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The family of inhibitors of DNA-binding (ID) proteins consists of
four members of basic helix-loop-helix (bHLH) transcription
factors lacking the DNA-binding domain (Norton et al, 1998a).
Therefore, they act as dominant-negative regulators of bHLH
proteins by forming transcriptionally inactive Id-bHLH protein
complexes (Riechmann et al, 1994; Riechmann and Sablitzky,
1995). ID proteins play key roles in the regulation of cell
differentiation during neurogenesis, lymphoiesis and angiogenesis.
Their functions also include the promotion of cell growth and cell
cycle progression, and apoptotic induction (Lyden et al, 1999;
Norton, 2000).
Regarding tumour cell proliferation, ID-1 inhibited the promo-
ter region of the tumour suppressor gene CDKN2A/p16, support-
ing the role of ID-1 as a potential oncogene (Alani et al, 2001).
Furthermore, ID proteins also inhibited the transformation-
specific sequence (ETS) transcription factors of an avian
erythroblastosis virus, E26 (Yates et al, 1999), which are able to
suppress p16 expression by binding to and activating its promoter.
This indicates that IDs might inhibit the p16 promoter, and
thereby increase tumour cell proliferation, through interactions
with ETS transcription factors directly and indirectly (Ohtani et al,
2001). Both IDs and ETS transcription factors have previously been
implicated in the regulation of angiogenesis (Lyden et al, 1999;
Wernert et al, 2003). The ID interactors–E protein transcription
factors E12 (also known as epididymal sperm-binding protein,
ELSPBP1), E47 (also known as E2A and TCF3), E2-2 (also known
as TCF4) and HEB (also known as TCF12) (Yan et al, 1997),
retinoblastoma protein (RB) (Lasorella et al, 2000) and ETS
proteins (Ohtani et al, 2001)–are all implicated in tumorigenesis.
Recently, several reports have shown that ID-1 protein can
induce cell proliferation and increase DNA synthesis, and that it
can immortalise mammalian cells in corporation with other
oncogenes (Norton and Atherton, 1998b; Alani et al, 1999). ID-1
overexpression has been found in several types of primary human
cancers including breast, pancreatic, prostate, nasopharyngeal,
melanoma and cervical cancers (Langlands et al, 2000; Lin
et al, 2000; Polsky et al, 2001; Schindl et al, 2001, 2003; Wang
et al, 2002; Ouyang et al, 2002a; Schoppmann et al, 2003; Lee et al,
2004; Straume and Akslen, 2005; Jang et al, 2006). IDs activate
VEGF-dependent mobilisation of circulating endothelial cells and
endothelial precursor cells from the bone marrow (Lyden et al,
2001). Further, ID-1 might act by transcriptional repression of
thrombospondin (TSP)-1, a well-known angiogenesis inhibitor
(Volpert et al, 2002). TSP-1 was more frequently expressed in
leiomyoma compared with uterine smooth muscle tumour of
uncertain malignant potential and leiomyosarcoma (Bodner-Adler
et al, 2006).
Previous studies reported, expression of ID-1 was shown as an
independent prognostic factor in cervical cancer with long-time
follow-up, even more significant in early-stage disease. Over
expression of ID-1 is associated with more aggressive behavior of
Received 10 July 2008; revised 15 September 2008; accepted
16 September 2008; published online 28 October 2008
*Correspondence: Professor J Fujimoto; E-mail: jf@gifu-u.ac.jp
British Journal of Cancer (2008) 99, 1557–1563
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
stumour cells in cervical cancer (Schindl et al, 2001). However, no
evidence clarifying the direct association between tumour
advancement and ID protein expression is available in human
primary cancer so far.
To elucidate the clinical implication of IDs in uterine cervical
cancers, we analysed the manner expression of ID proteins
in uterine cervical cancer progression according to clinical
backgrounds, their influence on the survival of the patients and
the association between ID mRNA expression and neoangio-
genesis, assessed by assessment of microvessel density (MVD).
MATERIALS AND METHODS
Patients and tissues
Prior informed consent for the following studies was obtained
from all patients and approval was given by the Research
Committee for Human Subjects, Gifu University School of
Medicine. Sixty patients ranging from 35 to 79 years of age with
uterine cervical cancers (stage I, 21 cases; stage II, 21 cases; and
stage III, 18 cases; squamous cell carcinoma (SCC), 42 cases and
adenocarcinoma (AD), 18 cases) underwent surgery at the
Department of Obstetrics and Gynecology, Gifu University School
of Medicine, between September 1998 and August 2004. Patient
prognosis was analysed in relation to a 36-month survival rate.
None of the patients had received any pre-operative therapy before
the uterine cervical cancer tissue was taken in surgery. A part of
each tissue of uterine cervical cancers was snap-frozen in liquid
nitrogen and stored at  801C to determine ID-1, ID-2 and ID-3
mRNA levels and those for immunohistochemistry were fixed with
10% formalin and embedded in paraffin wax. The clinical stage
of uterine cervical cancers was determined by International
Federation of Obstetrics and Gynecology (FIGO) classification
(International Federation of Obstetrics and Gynecology (FIGO)
News, 1989).
Immunohistochemistry
Sections (4mm) of formalin-fixed paraffin-embedded tissue
samples from uterine cervical cancers were cut with a microtome
and dried overnight at 371C on a silanised-slide (Dako,
Carpinteria, CA, USA). The protocol of universal Dako-labelled
Streptavidin–Biotin kit (Dako, Carpinteria, CA, USA) was followed
for each sample. Samples were deparaffinised in xylene at room
temperature for 30min, rehydrated with graded ethanol and
washed in phosphate-buffered saline (PBS). The samples were then
placed in 10mM citrate buffer (pH 6.0) and boiled in a microwave
for 10min for epitope retrieval. Endogenous peroxidase activity
was quenched by incubating tissue sections in 3% H2O2 for 10min.
The primary antibodies, rabbit anti-human ID-1 (SC-734, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA), mouse CD34
(Dako, Glostrup, Denmark) and rabbit anti-factor VIII-related
antigen (Zymed, San Francisco, CA, USA) were used overnight
at 41C at dilutions of 1:50, 1:40 and 1:2, respectively. The
slides were washed and biotinylated secondary antibody (Dako,
Carpinteria, CA, USA) was applied for 30min after rinsing in PBS,
after which streptavidin-conjugated horseradish peroxidase (Dako,
Carpinteria, CA, USA) was added for 30min. Slides were then
washed and treated with the chromogen 3,30–diaminobenzidine
(Dako, Carpinteria, CA, USA) for 5min, then rinsed in PBS, and
counterstained with Mayer’s haematoxylin, dehydrated in graded
ethanols, cleared in xylene and cover-slipped with a mounting
medium, Entellan New (Merck, Darmstadt, Germany). For
confirmation of the specificity for ID-1 antigen, we also used
another ID-1 (SC-488) rabbit polyclonal antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) and we have observed
the exact identified intensity and localisation of staining for ID-1
expression in tumour cells as ID-1 (SC-734) antibody. For the
negative controls, the primary antibodies of ID-1, CD34 and factor
VIII-related antigen were omitted and the corresponding
preimmune animal serums (rabbit, mouse and rabbit, respectively)
(Dako, Carpinteria, CA, USA) were used instead.
Assessment of histochemical score (histoscore)
All sections of immunohistochemical staining for ID-1 were
evaluated in a semiquantitative fashion according to the method
described by McCarty et al (1985), which considers both the
intensity and the percentage of cells stained in each of five
intensity categories. Intensities were classified as 0 (no staining),
1 (weak staining), 2 (distinct staining), 3 (strong staining) and 4
(very strong staining). For each stained section, a value-designated
histoscore was obtained by application of the following algorithm:
histoscore¼
P
(iþ1) Pi, where i and Pi represent intensity and
percentage of cells that stain at each intensity, respectively, and
corresponding histoscores were calculated separately. Results were
assigned to four groups according to their overall scores: weak,
o160; distinct, 161o, 4220; strong, 221o, 4280; very strong,
280o. Immunohistochemistry results were analysed by two
pathologists.
Assessment of microvessel density
The MVD was assessed with microvessel counts (MVCs) in
sequential tissue sections stained with mouse CD34 and rabbit
factor VIII-related antigen antibodies. Blood vessels with a clearly
defined lumen or a well defined linear vessel shape, but not single
endothelial cells, were taken into account for microvessel counting
(Giatromanolaki et al, 2001). Fives areas of highest vascular
density were chosen and microvessel counting was performed at
 200 magnification by two investigators. The MVCs were
determined as the mean of the vessel counts obtained from these
fields (Maeda et al, 1996).
Preparation of standard template for real-time reverse
transcription–polymerase chain reaction (RT–PCR)
Internal standard template for real-time PCR was produced by
PCR amplification using the primers of ID-1 gene, 418–782 in the
cDNA (ID-1-TS: 50-TTGGAGCTGAACTCGGAA-30 and ID-1-TAS:
50-TCTCTGGTGACTAGTAGGT-30); ID-2 gene, 907–1253 in the
cDNA (ID-2-TS: 50-CTAAGCAGACTTTGCCTTT-30 and ID-2-TAS:
50-CTGAAATAAAGCAGGCAATC-30); ID-3 gene, 686–1009 in the
cDNA (ID-3-TS: 50-GAACTTGTCATCTCCAACGA-30 and ID-3-
TAS: 50-CACGCTCTGAAAAGACCT-30). The DNA template was
purified using a GeneClean II kit (Qbiogene, Irvine, CA, USA).
The copy numbers of the standard template were determined
to quantitate ID-1, ID-2 and ID-3 mRNA level in samples for
real-time RT–PCR.
Real-time RT–PCR to amplify ID-1, ID-2 and ID-3 mRNAs
Total RNA was extracted with the acid guanidinium thiocyanate–
phenol–chloroform method (Chomczynski and Sacchi, 1987). The
total RNA (3mg) was reverse transcribed using Moloney murine
leukaemia virus reverse transcriptase (MMLV-RT, 200Uml
 1,
Invitrogen, Carlsbad, CA, USA) and the following reagents:
250mM Tris-HCl, pH 8.3, 375mM KCl, 15mM MgCl2, 0.1M
dithiothreitol, 10mM deoxynucleotide (deoxyadenosine, deoxy-
thymidine, deoxyguanosine and deoxycystidine) tri-phosphates
(dNTPs) mixture and random hexamers (Invitrogen) at 371C for
1h. The reaction mixture was heated for 5min at 941C to inactivate
MMLV-RTase.
Real-time PCR was performed with a Takara Ex Taq R-PCR kit,
Version 1.0 (Takara, Otsu, Japan), using a smart cycler system
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s(Cepheid, Sunnyvale, CA, USA). The reaction solution (25ml)
contained Takara Ex Taq HS (5Uml
 1), 10 R-PCR Buffer (Mg
2þ
free), 250mM Mg
2þ solution, 10mM dNTP mixture, SYBR Green I
(1:1000 dilution; CambrexBio Science, Rockland Inc., Rockland,
ME, USA) and 20mM of the primers of ID-1 gene, 545–675 in the
cDNA (ID-1-S: 50-ACGATCGCATCTTGTGTC-30 and ID-1-AS:
50-CTTGTTCTCCCTCAGATCC-30); ID-2 gene, 907–1026 in the
cDNA (ID-2-S: 50-CTAAGCAGACTTTGCCTTT-30 and ID-2-AS:
50-CATTCAGTAGGCTTGTGTC-30); ID-3 gene, 709–873 in the
cDNA (ID-3-S: 50-AAGGAGCTTTTGCCACTGA-30 and ID-3-AS:
50-CCAGGAAGGGATTTGGTGAA-30) with the transcribed total
RNA from the tissue and a serially diluted standard template. The
real-time PCR reactions were initially denatured by heating at 951C
for 30s, followed by 40 cycles consisting of denaturation at 941C
for 10s, annealing at 551C for 5s and extension at 721C for 20s.
A strong linear relationship between the threshold cycle and the
log concentration of the starting DNA copy number was always
shown (correlation coefficient 40.99). Quantitative analysis was
performed to determine the copy number of each sample.
Statistical analysis
Inhibitor of DNA-binding-1, ID-2 and ID-3 mRNA levels were
determined from three parts taken from each tumour, and each
sample was analysed in triplicate. ID-1 histoscores and mRNA
levels were compared using Student’s t-test. The 24-month survival
rate was calculated according to the Kaplan–Meier method, and
analysed with the log-rank test. The correlations between ID-1
histoscores and mRNA levels with MVCs were performed with
bivariate Pearson’s correlation. Differences were considered
significant when P was less than 0.05.
RESULTS
Inhibitor of DNA-binding-1 mRNA levels significantly increased
with increasing clinical stages (IoIIoIII; Po0.05) of uterine
cervical cancers, regardless of histopathological type and lymph
node metastasis (Figure 1). However, there was no significant
difference in ID-2 or ID-3 mRNA levels according to clinical stage,
histopathological type or lymph node metastasis in uterine cervical
cancers, as shown in Figure 1. These results prompted us to
concentrate our investigation on ID-1 in uterine cervical cancers.
Inhibitor of DNA-binding-1 staining was diffusely located in the
cancer cells. Although ID-1 expression in stroma cells was weak or
negative, perivascular cells of intratumoral microvessels were
strongly positive in all cases (Figure 2A, a representative case,
46-year-old patient, stage IIb, squamous cell carcinoma). Because
ID-1 is not a transcription factor per se, it lacks the nuclear
localisation signal found on many basic HLH proteins but gives a
cytoplasmic signal instead (Maruyama et al, 1999; Lin et al, 2000;
Schindl et al, 2001). ID-1 diffuse cytoplasmic staining was seen
from moderate to strong intensity in most cases whereas nuclear
staining was observed only occasionally (Figure 2B).
Inhibitor of DNA-binding-1 histoscore in cancer cells signi-
ficantly (Po0.001) correlated with corresponding mRNA levels
in each tissue, as shown in Figure 3. Although there was no signi-
ficant difference in ID-1 histoscores in cancer cells according to
histopathological type and lymph node metastasis, ID-1 histoscores
significantly (IoIIoIII; Po0.05) increased with increased clinical
stages of uterine cervical cancers (Figure 4), as did ID-1 mRNA.
Furthermore, the 60 patients who underwent surgery were
arbitrarily divided into two equal groups based on ID-1 histoscores
and mRNA levels, with the midpoint being a histoscore of 140 and
mRNA of 1.6 10
6 copiesmg
 1 total RNA, respectively. The two
groups, determined independently by the ID-1 histoscores and
mRNA levels, consisted of exactly the same patients. The prognosis
of the 30 patients with high ID-1 (4140 histoscore and 41.6 10
6
copiesmg
 1 total RNA) in uterine cervical cancers was poor (60%),
whereas the 36-month survival rate of the other 30 patients with
low ID-1 (o140 histoscore and o1.6 10
6 copiesmg
 1 total RNA)
was higher (83%), as shown in Figure 5.
Inhibitor of DNA-binding-1 expression was very weak in
endothelial cells although Factor VIII-related antigen and CD34
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Figure 1 Inhibitor of DNA-binding-1, ID-2 and ID-3 mRNA levels in uterine cervical cancers classified according to clinical stage, histopathological type
and lymph node metastasis. Clinical staging of uterine cervical cancers was done according to FIGO. Each level is the mean±s.d. of nine determinations.
SCC, squamous cell carcinoma; AD, adenocarcinoma. *Po0.05; **Po0.001.
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sexpression were strong. In tissue sections, weak ID-1 expression
was associated with low MVD whereas strong ID-1 expression was
associated with abundant microvessels. The ID-1 histoscores in
cancer cells significantly correlated with MVC-CD34 (MVCs
determined by immunohistochemistry for CD34; r¼0.833,
Po0.0001) and MVC-F-VIII (MVCs determined by immunohisto-
chemistry for factor VIII-related antigen; r¼0.742, Po0.0001);
and ID-1 mRNA levels also correlated with MVC-CD34 (r¼0.892,
Po0.0001) and MVC-F-VIII (r¼0.768, Po0.0001), as shown in
Figure 6.
DISCUSSION
This study is, to our knowledge, the first to reveal that ID-1
expression in the cancer cells increased with tumour advancement
of uterine cervical cancers. Also, the patients with high ID-1
expression had a lower survival rate compared with patients with
low ID-1 expression. Negative prognostic impacts of increased ID-1
expression have been shown in breast cancers (Schoppmann et al,
2003), pancreatic cancers (Lee et al, 2004), melanoma (Straume and
Akslen, 2005), cervical cancers (Schindl et al,2 0 0 1 ) ,a n d
ovarian carcinomas (Schindl et al, 2003). This is in line with
our finding. Therefore, ID-1 is recognised as a novel indicator of
tumour advancement and patient prognosis in uterine cervical
cancer.
Previously, no correlation between expression of ID proteins
and angiogenesis, assessed by MVD was observed in cervical
cancers (Schindl et al, 2001). But contrary to their finding, present
study showed that mostly diffuse to strong cytoplasmic expression
of ID-1 in tumour cells and also very weak ID-1 expression in
endothelial cells. Moreover, ID-1 expression not only correlated
with microvessel counts but also correlated significantly with
histoscore. These data indicate that ID-1 overexpression is found
to be closely related to tumour angiogenesis, a higher density of
intratumoral vessel and poor survival in cervical cancer. Therefore,
ID-1 is a candidate for angiogenic mediator as the clinical
relevance of angiogenesis assessed by MVD.
ID-1 Negative control
I
III IV
II
Figure 2 (A). Immunohistochemical staining for positive and negative ID-1 staining in squamous cell carcinoma of uterine cervical cancers.
(B). Immunohistochemical staining for ID-1 representing cases from each stage in uterine cervical cancers. Weak staining (score 111) stage I; distinct (score
167) stage II; strong (score 264) stage III and very strong (score 392) stage IV, showing strong cytoplasmic expression in tumour cells. Overall scores: weak,
o160; distinct, 161o, 4220; strong, 221o, 4280; very strong, 280o. (original magnification  400). Rabbit anti-human ID-1 (SC-734, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) was used at a dilution of 1:50 as the primary antibody (original magnification  200).
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sAngiogenesis is essential for development, growth and advance-
ment of solid tumours (Folkman, 1985). The angiogenic factors
vascular endothelial growth factor (VEGF) (Fujimoto et al, 1999a)
and thymidine phosphorylase identified with platelet-derived
endothelial cell growth factor (Fujimoto et al, 1999b,c, 2000) and
interleukin (IL-8) along with the angiogenic transcriptional factor
ETS-1 (Fujimoto et al, 2002) work on angiogenesis in uterine
cancers.
Inhibitor of DNA-binding-1 is a regulator of basic HLH-
mediated transcription (Norton et al, 1998a) and causes cells to
pass a mitogen-restricted point in late G1 phase (Le Jossic et al,
1994). Therefore, ID-1 has been suggested as responsible for some
of the changes in gene expression that lead to increased growth
and invasion of tumour cells (Lyden et al, 1999). Moreover, the
ectopic expression of ID-1 increases the proliferation, migration,
invasion and metastasis of breast cancer cells (Desprez et al, 1998;
Lin et al, 2000). Although ID-1 has been shown to interact with
various cell cycle regulators (Alani et al, 2001; Ohtani et al, 2001),
ID-1 seems to be an essential factor in the promotion of G1/S cell
cycle transition in certain cancers by inactivating of p16 and
increasing of CDK4 activity/RB (Polsky et al, 2001; Ouyang et al,
2002b; Singh et al, 2002). However, additional studies are required
to determine the mechanism of interaction between ID-1 and
various cell cycle regulators.
Recently, TSP-1, an endogenous inhibitor of neovascularisation
has been identified as a target of ID-1 that is negatively regulated
by ID-1 in the regulation of angiogenesis (Volpert et al,
2002). Thrombospondin-1 suppresses angiogenesis by inhibiting
endothelial cell proliferation and inducing endothelial cell
apoptosis (Zhang et al, 2003). For example, in the ID-1  /  mice,
transcription of TSP-1 is increased, which is associated with
inhibition of bFGF and VEGF-induced angiogenesis. This pheno-
type can be reversed by inactivation of TSP-1 function (Volpert
et al, 2002). In addition, microvessel density count was negatively
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sassociated with the intensity of TSP-1 expression in uterine
cervical cancer (Wu et al, 2004). An inverse relation between ID-1
and TSP-1 expression supports the significant role of ID-1 in the
regulation of this complex multitarget protein (Straume and
Akslen, 2005). These previous studies suggested that due to ID-1
suppression, TSP-1 expression might be lost with tumour
advancement, resulting in drastic tumour angiogenesis that
accelerates tumour advancement. These provide evidence that
clarifies the association between ID-1 overexpression and tumour
angiogenesis in human primary cancer.
Inhibitor of DNA-binding-1 expression was high in two
androgen-independent prostate cancer cell lines, DU145 and
PC3, but its expression is undetectable in the androgen-dependent
cell line LNCaP under serum-free conditions (Ling et al, 2003). As
prostate cancer progression and aggressiveness are judged by its
response to androgen, these results support the role of ID-1
expression in tumour progression. Furthermore, ID-1 expression
was higher in highly aggressive breast cancer cell lines such as
MDA-MB321 and MDA-MB-435 compared with the less aggressive
cell lines such as MCF7 and T47D. Ectopic ID-1 expression in
T47D cells led to increased cell growth, invasion ability and
reduced sensitivity to sex hormones (Lin et al, 2000). In addition,
stable transfection of breast cancer cells with the antisense ID-1
vector also reduces lung metastasis after their inoculation into
nude mice (Fong et al, 2003). These results support the role of ID-1
in metastasis of breast cancer and also suggest inactivation of ID-1
as a therapeutic strategy in the treatment of metastatic breast
cancer. Therefore, ID-1 protein may be an important new target
molecule for antiangiogenic drug design in cancer treatment. It is
strongly suggested that transcriptional suppression of TSP-1 by
ID-1 may play an important part in promoting angiogenesis in the
uterine cervical cancers.
To conclude, this study suggests that ID-1 promotes tumour
advancement of uterine cervical cancer through angiogenesis,
leading to poor prognosis, and provides a novel therapeutic
approach in uterine cervical cancers.
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